Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Lymphoma

Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC

Bone Marrow Transplantation volume 51, pages 1184–1190 (2016)Cite this article

Subjects

Abstract

Poly-chemotherapy plus rituximab followed by autologous stem cell transplantation (auto-SCT) is standard care for untreated young patients with mantle cell lymphoma (MCL). Despite this intensive treatment, transplant patients remain highly susceptible to relapse over time. The French SFGM-TC performed a national survey on reduced-intensity conditioning allogeneic stem cell transplantation (RIC-allo-SCT) for fit relapsed/refractory patients who failed after auto-SCT (n=106). Median times of relapse after auto-SCT, and from auto-SCT to RIC-allo-SCT were 28 months and 3.6 years, respectively. Sixty per cent of patients received at least three lines of treatment before RIC-allo-SCT. Conditioning regimens for RIC-allo-SCT were heterogeneous. Twenty patients experienced grade III/IV aGvHD, extensive cGvHD was reported in 28 cases. Median follow-up after RIC-allo-SCT was 45 months. Median PFS after RIC-allo-SCT was 30.1 months and median overall survival was 62 months. Treatment-related mortality (TRM) at 1 year and 3 years were estimated at 28% and 32%, respectively. A total of 52 patients died; major causes of death were related to toxicity (n=34) and MCL (n=11). Patients in good response before RIC-allo-SCT experienced a better PFS and OS. Our work highlights the need for new RIC-allo-SCT MCL-tailored approaches to reduce TRM, and early and late relapse.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

References

  1. Campo E, Rule S . Mantle cell lymphoma: evolving management strategies. Blood 2015; 125: 48–55.

    Article  CAS  Google Scholar 

  2. Dreyling M, Thieblemont C, Gallamini A, Arcaini L, Campo E, Hermine O et al. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol 2013; 24: 857–877.

    Article  CAS  Google Scholar 

  3. Dietrich S, Boumendil A, Finel H, Avivi I, Volin L, Cornelissen J et al. Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol 2014; 25: 1053–1058.

    Article  CAS  Google Scholar 

  4. Touzeau C, Leux C, Bouabdallah R, Roussel M, Delarue R, Bouabdallah K et al. Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC. Ann Hematol 2013; 93: 233–242.

    Article  Google Scholar 

  5. Robinson S, Dreger P, Caballero D, Corradini P, Geisler C, Ghielmini M et al. The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma. Leukemia 2015; 29: 464–473.

    Article  CAS  Google Scholar 

  6. Leux C, Maynadié M, Troussard X, Cabrera Q, Herry A, Le Guyader-Peyrou S et al. Mantle cell lymphoma epidemiology: a population-based study in France. Ann Hematol 2014; 93: 1327–1333.

    Article  Google Scholar 

  7. Corradini P, Dodero A, Farina L, Fanin R, Patriarca F, Miceli R et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 2007; 21: 2316–2323.

    Article  CAS  Google Scholar 

  8. Tam CS, Bassett R, Ledesma C, Korbling M, Alousi A, Hosing C et al. Mature results of the MD Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 2009; 113: 4144–4152.

    Article  CAS  Google Scholar 

  9. Cook G, Smith GM, Kirkland K, Lee J, Pearce R, Thomson K et al. Outcome following reduced-intensity allogeneic stem cell transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2010; 16: 1419–1427.

    Article  Google Scholar 

  10. Le Gouill S, Mohty M, Guillaume T, Gastinne T, Moreau P . Allogeneic stem cell transplantation in mantle cell lymphoma: where are we now and which way should we go? Semin Hematol 2011; 48: 227–239.

    Article  Google Scholar 

  11. Le Gouill S, Kröger N, Dhedin N, Nagler A, Bouabdallah K, Yakoub-Agha I et al. Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience. Ann Oncol 2012; 23: 2695–2703.

    Article  CAS  Google Scholar 

  12. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008; 111: 558–565.

    Article  CAS  Google Scholar 

  13. Maris MB, Sandmaier BM, Storer BE, Chauncey T, Stuart MJ, Maziarz RT et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004; 104: 3535–3542.

    Article  CAS  Google Scholar 

  14. Hertzberg M, Grigg A, Gottlieb D, Szer J, Roberts A, Hoyt R et al. Reduced-intensity allogeneic haemopoietic stem cell transplantation induces durable responses in patients with chronic B-lymphoproliferative disorders. Bone Marrow Transplant 2006; 37: 923–928.

    Article  CAS  Google Scholar 

  15. Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cook G et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004; 104: 3865–3871.

    Article  CAS  Google Scholar 

  16. Urbano-Ispizua A, Pavletic SZ, Flowers ME, Klein JP, Zhang M-J, Carreras J et al. The impact of graft-versus-host disease on the relapse rate in patients with lymphoma depends on the histological subtype and the intensity of the conditioning regimen. Biol Blood Marrow Transplant 2015; 21: 1746–1753.

    Article  Google Scholar 

  17. Robinson SP, Taghipour G, Canals C et al. Reduced-intensity conditioning and allogeneic stem cell transplantation in mantle cell lymphoma: update from the lymphoma working party of the EBMT. Hamburg, Germany 2006; 29: 464–473.

    Google Scholar 

  18. Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012; 367: 520–531.

    Article  CAS  Google Scholar 

  19. Le Gouill S . Rituximab maintenance versus wait and watch after four courses of R-DHAP followed by autologous stem cell transplantation in previously untreated young patients with mantle cell lymphoma: first interim analysis of the phase III prospective Lyma trial, a Lysa Study. ASH 2014 Abstract 146.

  20. Pott C, Hoster E, Delfau-Larue M-H, Beldjord K, Böttcher S, Asnafi V et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood 2010; 115: 3215–3223.

    Article  CAS  Google Scholar 

  21. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369: 507–516.

    Article  CAS  Google Scholar 

  22. Delfau-Larue M-H, Klapper W, Berger F, Jardin F, Briere J, Salles G et al. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. Blood 2015; 126: 604–611.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, University Hospital, Nantes, France

    B Tessoulin, P Chevallier & S Le Gouill

  2. INSERM team 10 UMR 892, CRCNA, Nantes, France

    B Tessoulin & S Le Gouill

  3. Department of Hematology, University Hospital, Montpellier, France

    P Ceballos

  4. Department of Hematology, Paoli Calmettes, Marseille, France

    D Blaise

  5. Department of Hematology, University Hospital, Clermont-Ferrand, France

    O Tournilhac

  6. Department of Hematology, University Hospital, Lille, France

    J Gauthier

  7. Department of Hematology, University Hospital, Poitiers, France

    N Maillard

  8. Department of Hematology, University Hospital, Bordeaux, France

    R Tabrizi

  9. Department of Hematology, Pitie Salpetriere, Paris, France

    S Choquet

  10. Department of Hematology, University Hospital, Grenoble, France

    S Carras

  11. Department of Hematology, University Hospital, Angers, France

    N Ifrah

  12. Department of Hematology, University Hospital, Brest, France

    G Guillerm

  13. Department of Hematology, University Hospital-Saint Antoine, Paris, France

    M Mohty

  14. Department of Hematology, Centre Henri-Becquerel, Rouen, France

    H Tilly

  15. Department of Hematology, Saint Louis Hospital, Paris, France

    G Socie

  16. Department of Hematology, Institut de Cancerologie de la Loire, Saint Etienne, France

    J Cornillon

  17. Department of Hematology, Necker Hospital, Paris, France

    O Hermine

  18. Department of Hematology, University Hospital, Besancon, France

    É Daguindau

  19. Department of Hematology, University hospital, Lyon, France

    E Bachy

  20. Department of Hematology, University Hospital, Limoges, France

    S Girault

  21. Department of Hematology, University Hospital, Rennes, France

    T Marchand

  22. University Cancer Institute, Toulouse, France

    L Oberic

  23. Department of Hematology, University Hospital, Caen, France

    O Reman

  24. Department of Epidemiology, University Hospital of Nantes, Nantes, France

    C Leux

  25. Centre d’Investigation Clinique en Cancérologie (CI2C), CHU de Nantes, Nantes, France

    S Le Gouill

Authors
  1. B Tessoulin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Ceballos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P Chevallier
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D Blaise
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. O Tournilhac
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J Gauthier
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. N Maillard
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. R Tabrizi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S Choquet
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S Carras
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. N Ifrah
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. G Guillerm
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. M Mohty
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. H Tilly
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. G Socie
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. J Cornillon
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. O Hermine
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. É Daguindau
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. E Bachy
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. S Girault
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. T Marchand
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. L Oberic
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. O Reman
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. C Leux
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. S Le Gouill
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Le Gouill.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on Bone Marrow Transplantation website

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Tessoulin, B., Ceballos, P., Chevallier, P. et al. Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC. Bone Marrow Transplant 51, 1184–1190 (2016). https://doi.org/10.1038/bmt.2016.102

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2016.102

This article is cited by

Search

Advanced search

Quick links